Tumor-associated macrophages in immune microenvironment of lung cancer

Abstract

DING Yi-Hui, ZHANG Kai, HU Yue, LIU Li. Tumor-associated macrophages in immune microenvironment of lung cancer[J]. Journal of International Oncology, 2014, 41(11): 830-833.

［1］ Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014［J］. CA Cancer J Clin, 2014, 64(1): 929. ［2］ Schmieder A, Michel J, Schnhaar K, et al. Differentiation and gene expression profile of tumorassociated macrophages［J］. Semin Cancer Biol， 2012, 22(4):289297. ［3］ Shirabe K, Mano Y, Muto J, et al. Role of tumorassociated macrophages in the progression of hepatocellular carcinoma［J］. Surg Today， 2012, 42(1):17. ［4］ Wang XF, Wang HS, Zhang F, et al. Nodal promotes the generation of M2like macrophages and downregulates the expression of IL12［J］. Eur J Immunol， 2014， 44(1):173183. ［5］ Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment［J］. Trends Immunol, 2012, 33(3):119126. ［6］ Quatromoni JG, Eruslanov E. Tumorassociated macrophages: function, phenotype, and link to prognosis in human lung cancer［J］. Am J Transl Res, 2012, 4(4):376389. ［7］ Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer［J］. Expert Opin Biol Ther， 2012, 12(7):923937. ［8］ Chung FT, Lee KY, Wang CW, et al. Tumorassociated macrophages correlate with response to epidermal growth factor receptortyrosine kinase inhibitors in advanced nonsmall cell lung cancer［J］. Int J Cancer, 2012, 131(3):E227E235. ［9］ Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NYESO1［J］. N Engl J Med, 2008, 358(25):26982703. ［10］ Reck M. What future opportunities may immunooncology provide for improving the treatment of patients with lung cancer?［J］. Ann Oncol， 2012，23 Suppl 8:viii2834. ［11］ Brahmer JR. Harnessing the immune system for the treatment of nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(8):10211028. ［12］ Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for nonsmall cell lung cancer: novel approaches to improve patient outcome［J］. J Thorac Oncol， 2011, 6(10):17631773. ［13］徐燕, 王孟昭. 非小细胞肺癌免疫治疗进展［J］. 中国肺癌杂志, 2014, 17(1): 3441. ［14］ Lievense LA, Bezemer K, Aerts JG, et al. Tumorassociated macrophages in thoracic malignancies［J］. Lung Cancer, 2013, 80(3):256262. ［15］ Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers［J］. J Transl Med， 2011， 9: 216. ［16］ Wang R, Zhang J, Chen S, et al. Tumorassociated macrophages provide a suitable microenvironment for nonsmall lung cancer invasion and progression［J］. Lung Cancer, 2011, 74(2):188196. ［17］ Zhang Y, Choksi S, Chen K, et al. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumorassociated macrophages［J］. Cell Res, 2013, 23(7):898914. ［18］ Zhang Y, Choksi S, Liu ZG. Butylated hydroxyanisole blocks the occurrence of tumor associated macrophages in tobacco smoke carcinogeninduced lung tumorigenesis［J］. Cancers (Basel), 2013， 5(4): 16431654. ［19］ Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin［J］. Cancer Cell, 2013, 23(2):249262. ［20］ Welsh TJ, Green RH, Richardson D, et al. Macrophage and mastcell invasion of tumor cell islets confers a marked survival advantage in nonsmallcell lung cancer［J］. J Clin Oncol, 2005, 23(35):89598967. ［21］ Ohri CM, Shikotra A, Green RH, et al. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival［J］. Eur Respir J, 2009, 33(1):118126. ［22］ Shao R. YKL40 acts as an angiogenic factor to promote tumor angiogenesis［J］. Front Physiol, 2013, 4(122):19. ［23］ Thm I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL40An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer［J］. Cancer, 2010, 116(17): 41144121. ［24］ Standiford TJ, Kuick R, Bhan U, et al. TGFβinduced IRAKM expression in tumorassociated macrophages regulates lung tumor growth［J］. Oncogene， 2011, 30(21):24752484. ［25］ Kühnemuth B, Mühlberg L, Schipper M, et al. CUX1 modulates polarization of tumorassociated macrophages by antagonizing NFκB signaling［J］. Oncogene， 2013， In press.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[5]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.Research progress of myeloid-derived suppressor cells in tumor angiogenesis[J]. Journal of International Oncology, 2024, 51(1): 50-54.
[6]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[7]	Zhang Li, Xiang Zhuo, Wang Qiang, Bi Jingwang.Research progress of cytokine release syndrome related to CAR-T immunotherapy[J]. Journal of International Oncology, 2023, 50(6): 377-381.
[8]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230.
[9]	Ding Hao, Ying Jintao, Fu Maoyong.Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(4): 231-235.
[10]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai.Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy[J]. Journal of International Oncology, 2023, 50(3): 169-173.
[11]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[12]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng.Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection[J]. Journal of International Oncology, 2023, 50(12): 711-716.
[13]	Zhu Yi, Chen Jian.Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects[J]. Journal of International Oncology, 2023, 50(12): 729-733.
[14]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin.Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging[J]. Journal of International Oncology, 2023, 50(11): 655-660.
[15]	Xie Lulu, Ding Jianghua.Progress of immunotherapy-based strategy in triple-negative breast cancer[J]. Journal of International Oncology, 2023, 50(11): 672-676.

Tumor-associated macrophages in immune microenvironment of lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments